Perfect Timing: Amarillo Gold Achieves Key Milestone in Rising Gold Market
Source: Marc Davis  (5/23/16)
Marc Davis of BNWNews profiles Amarillo Gold, a company that is finally poised to capitalize on a resurgent gold market. More >

How to Take Advantage of Multi-Week Correction in Gold and Silver
Source: Jack Chan  (5/23/16)
Technical analyst Jack Chan finds gold stocks are on a short-term sell signal and reveals an excellent entry point. More >

Ares-American Capital Merger Positive for Long-Term Investors
Source: Adrian Day  (5/23/16)
Investment adviser Adrian Day discusses the merger announced today between Ares Capital and American Capital. More >

Two Overlooked Streaming Stocks with Huge Upside Potential
Source: Jason Hamlin for The Gold Report  (5/19/16)
Streaming/royalty stocks have been darlings of the commodity investment world. In the precious metals sector, this type of company provides financing for mining companies in the form of an upfront cash payment in exchange for a percentage of production or revenues from the mine. Jason Hamlin of Gold Stock Bull profiles two streamers often overlooked by investors. More >

With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016
Source: The Life Sciences Report  (5/18/16)
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company. More >

Two Companies Poised to Catch Up to Gold Peer Group
Source: Brien Lundin, Gold Newsletter  (5/17/16)
After a mad dash to the upside for gold and a similar dash to the downside for the U.S. dollar, investors are getting their bearings once again. April's disappointing jobs report refocused everyone on the potential economic slowdown and a still-dovish Fed. Brien Lundin of Gold Newsletter paints the big picture of how speculation over the Fed's actions to raise interest rates is affecting gold and gold equities, and he discusses two companies that have not appreciated as much as their peers but are likely to soon catch up. More >

Goldcorp Went Ahead and 'Made My Day'
Source: Michael Ballanger  (5/16/16)
Michael Ballanger expounds on the Goldcorp/Kaminak deal and what it means for the gold market, and he dissects the most recent COT report. More >

Divergence Between Oil and Oil Stocks Signals Decline in Oil-Related ETFs
Source: Jack Chan for The Energy Report  (5/16/16)
Technical analyst Jack Chan reports the energy sector cycle is down and a multiweek correction is in progress, and discusses what that means. More >

Gold Speculation at All-Time High, but Gold Price Remains Below 2015 High
Source: Jack Chan for The Gold Report  (5/14/16)
Technical analyst Jack Chan reports that although gold speculation is at an all-time high, the gold price has not followed suit. More >

Double-Digit Yields from Around the World
Source: Adrian Day  (5/13/16)
In this bulletin, Adrian Day reviews three companies with strong yields. All three are under some pressure, but equally all are solid companies with very attractive yields. More >

Goldcorp Is Back and Spending: Could West Red Lake Gold Mines Be Next?
Source: Gwen Preston, Resource Maven  (5/13/16)
Goldcorp is fresh off an announced transaction of $520M for Kaminak Gold, which is a big win for the industry. The company has been quietly putting dollars in juniors, like $16M in Gold Standard Ventures, and there could be more to come. In this article, Resource Maven Gwen Preston discusses possible target West Red Lake Gold Mines and how this company is shaping up to take advantage of the initial turnaround in the market. More >

Three Overlooked, Undervalued Picks for Today's Energy Market
Source: Chen Lin   (5/12/16)
The energy sector is a tricky place to invest right now, with a fine line separating the next bankruptcy candidate from a tenbagger. Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? helps investors navigate this minefield with three companies he believes will come out on top. More >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Source: George S. Mack of The Life Sciences Report  (5/11/16)
Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully. More >

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
Source: Special to The Life Sciences Report  (5/11/16)
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications. More >

Stan Druckenmiller: The Bull Market Is Exhausted; Make the Move to Gold
Source: The Gold Report  (5/10/16)
Legendary investor Stan Druckenmiller, founder of Duquesne Capital Management LLC, told the Sohn Investment Conference in New York last week that he is bullish on gold and bearish on the stock market. Gold, he told the conference, "is our largest currency allocation." More >

When Will Uranium Emerge from the Shadow of Fukushima?
Source: The Energy Report  (5/9/16)
Joe Reagor of ROTH Capital Partners explains the factors that have kept uranium spot prices down, how much longer they will be in effect, and why uranium should be on investors' radar screens today. He also discusses four uranium companies that are in position to benefit from the looming uranium shortage. More >

After COT Data Shocker, No Surprise Gold Is Down
Source: Jack Chan for The Gold Report  (5/9/16)
Technical analyst Jack Chan shows why Friday's COT data was so shocking and what it means for gold. More >

Energy Sector Showing Sell Signals
Source: Jack Chan for The Energy Report  (5/9/16)
Technical analyst Jack Chan highlights sell signals in the energy sector. More >

Commercial Gold 'Hedgers' Turn Up the Heat
Source: Michael Ballanger  (5/7/16)
Michael Ballanger discusses the most recent COT report, which shows levels not seen since 2010–2011. More >

Gold and Silver Companies with the Potential to Move the Needle
Source: Patrice Fusillo of The Gold Report  (5/5/16)
The two times mining companies add the most value are upon first discovery and when they are nearing development and production. Joe Reagor of ROTH Capital Partners focuses on the latter group, and in this interview with The Gold Report, he discusses a handful of gold and silver companies poised to move up the value curve even if gold and silver don't go up. More >

Give me Facts or at Least Logical Opinions
Source: Bob Moriarty  (5/5/16)
Bob Moriarty of 321Gold busts the myth of a Comex bank and examines the role of small speculators in commodities markets. More >

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
Source: Special to The Life Sciences Report  (5/4/16)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSomeâ„¢ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. More >

Delving Deep into Immune Pharmaceuticals' Diverse Pipeline
Source: Jason Napodano  (5/4/16)
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future. In this article for The Life Sciences Report, analyst Jason Napodano digs into the company's pipeline and investment potential. More >

Some of Brien Lundin's Precious Metals Picks Are Up More Than 400%. What Is Next?
Source: Patrice Fusillo of The Gold Report  (5/3/16)
A battle royale is brewing between gold bulls and commercial traders who are short gold, says Brien Lundin, publisher of Gold Newsletter. That tug of war, which should play out in the coming weeks, could result in either a severe correction or a spectacular rise in the price of gold and silver. No matter which way it goes, in this interview with The Gold Report, Lundin recommends that investors continue to look at companies with world-class resources that are still being priced at a fraction of what their values should be. Lundin should know; some of his recommendations are up more than 400% from December and January. More >

If A=B and B=C, Does A=C?
Source: Bob Moriarty  (5/3/16)
No need to listen to the "experts" to understand the ins and outs of commodities markets, according to Bob Moriarty of 321Gold. If investors use common sense and basic tools available online, they too can be successful. More >